For research purposes only. Not for human consumption. For use by licensed researchers only.
The CJC-1295 (No DAC) / Ipamorelin Blend is a research combination of a short-acting GHRH analogue and a selective ghrelin receptor agonist. Designed to study synergistic growth hormone stimulation, this blend activates two distinct receptor pathways for more comprehensive GH axis investigation.
Mechanism of Action
CJC-1295 (No DAC) binds GHRH receptors on pituitary somatotrophs to stimulate GH synthesis, while Ipamorelin acts through the separate GHS-R1a ghrelin receptor to amplify GH secretion. Research indicates the combination creates a more pronounced and physiologically mimetic GH pulse than either peptide alone, without significant cortisol or prolactin elevation.
Research Applications
- Synergistic growth hormone secretion research
- Pituitary GH pulse amplitude and frequency studies
- IGF-1 upregulation and downstream signaling research
- Muscle protein synthesis and body composition models
- Dual-receptor GH axis regulation studies
Research Grade Peptide
| Compound | CJC-1295 (No DAC) / Ipamorelin Blend |
| Strength | 5 mg / 5 mg |
| Vial Size | 3 mL |
| Vial Color | Clear |
| Form | Lyophilized Powder |
| Purity | >98% (HPLC verified) |
| Price | $95.00 |
This compound is provided strictly for in vitro and laboratory research. It has not been evaluated by the FDA and is not intended for diagnostic, therapeutic, or human use. Available to licensed researchers only.